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Background: The development of enterocutaneous ﬁstula (ECF) is one of the most challenging compli-
cations encountered in colorectal surgery. Currently, only two supra-regional centres are nationally
designated in the United Kingdom to treat ECF patients. The aim of this study was to assess clinical
outcome measures following the implementation of an ECF service at The Royal London Hospital.
Methods: All patients diagnosed with enterocutaneous ﬁstula between December 2005 and November
2011 were recruited to the study. Clinical outcomes analysed included successful ECF closure, number of
surgical procedures required for successful ECF closure, re-ﬁstulation rates and morbidity/mortality data.
Results: 41 patients (20M:21F) of median age 54 years (range, 16e81) were studied. Patients had un-
dergone a median of 4 (range, 1e18) operations prior to referral. Eleven ﬁstulas (27%) healed sponta-
neously. Of the remaining 30 patients, 5 (17%) died before surgery due to uncontrollable sepsis and 6
(20%) refused surgical intervention and were managed conservatively. Nineteen patients (63%) under-
went deﬁnitive surgical repair requiring a median of 1 (range, 1e2) operations, with recurrent ﬁstulation
reported in 4 patients (21%). No intra-operative mortality was encountered. Two (11%) patients died
postoperatively due to cardio-respiratory complications.
Conclusions: These data compare favourably with outcome measures reported by designated national
centres, suggesting ECF patients can be safely managed closer to home in regional units that have the
appropriate expertise. Nevertheless, management of this condition remains critically dependent upon a
dedicated multidisciplinary team approach.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
An enterocutaneous ﬁstula (ECF) is one of the most challenging
conditions encountered in surgical practice, particularly when
associated with septic, metabolic and nutritional complications
seen in Type II intestinal failure. Type I intestinal failure is self-
limiting, commonly seen after abdominal surgery necessitating
short-term ﬂuid and nutritional support.1 A wide range of pathol-
ogies are associated with ECF development including: diverticular
or inﬂammatory bowel disease, malignancy, mesenteric throm-
bosis, multiple laparotomies, radiation enteritis, intra-abdominal
sepsis, strangulated herniae, trauma, tuberculosis and volvulus.2e7Research and Surgical Inno-
entistry, 1st Floor, Abernethy
51; fax: þ44 020 7377 7283.
ras).
ciates Ltd. Published by Elsevier LtMany patients with ECF suffer multiple complications as a result
of this disease process, most commonly sepsis, malnutrition and
electrolyte abnormalities. Historically, mortality rates were
considerable, in excess of 50%, particularly in the presence of
persistent malnutrition or a high ﬁstula output. A reduction in
overall mortality ﬁgures has been achieved following identiﬁcation
of the key tenets of ECF management: nutritional support, ﬂuid
management, sepsis control and wound/skin care.8e15 While the
contemporary management of this condition has evolved, these
principles still remain central to the care of this patient group. A
staged approach is now frequently implemented in the manage-
ment of patients with ECF including recognition of ﬁstulation,
control of septic complications and catabolic metabolism, anatomic
deﬁnition with ECF localization and delayed deﬁnitive surgical
repair.16
Nevertheless, prognosis following the development of ECF re-
mains dependent on a variety of factors including the: site(s) of
origin; number of ﬁstula(e); output of the ﬁstula(e); and, baselined. All rights reserved.
Table 1
Demographic and pathophysiological characteristics of ECF patients.
Median age 54 (range: 16e81)
Male:female 20:21
Median ASA grade 2 (range: 1e3)
Median co-morbidities 3 (range: 0e7)
Internal/external referrals 26/15
Median operations before referral 4 (range, 1e18)
Median number of ﬁstula(e) 1 (1e3)
Origin of ﬁstula(e) for each patient 39 small bowel
2 small bowel and colon
Previous abdominal surgery 34
Number of patients with IBD 7
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of an adequate intestinal failure and ﬁstula management pro-
gramme directed by a dedicated medical and surgical team is an
additional critical prognostic factor. Currently the majority of this
patient group are treated in two supra-regional nationally desig-
nated UK intestinal failure units. Recent data, however, suggest that
ECF patients can also be safely managed in regional units with the
necessary expertise.17
The primary aim of this studywas to review the clinical outcome
measures of The Royal London Hospital Intestinal Failure Service to
determine whether surgery performed for Type II intestinal failure
in our centre is comparable to national standards.
2. Methods
An analysis of retrospectively collected data was performed for all patients with
enterocutaneous ﬁstulae (ECF) treated by our service from December 2005 to
November 2011.
2.1. Multi-disciplinary team
All patients were managed by a multi-disciplinary intestinal failure team
comprising consultant colorectal surgeons, consultant gastroenterologists, inter-
ventional radiologists, specialist nursing staff, dieticians, pharmacists, physiother-
apists and occupational therapists. The standardised management strategy adopted
at our institution is similar to that previously reported.20
2.2. Management of ﬁstula output
At initial assessment oral intake was minimised to facilitate estimation of both
ﬁstula and stoma output. Losses were replaced intravenously with concomitant
correction of serum electrolyte imbalances. Oral intake was then reintroduced and
included both high-caloriﬁc nutritional drinks and yoghourts. Supplementary
nasogastric feeding was instituted where necessary. When the combined ECF and
faecal output was greater than 1.5 L/day, attempts were made to minimise losses in
order to discontinue supplementary intravenous ﬂuid rehydration. Intake of ﬂuids
low in sodium was limited to 0.5 L/day when necessary; however, patients were
advised to that an unlimited intake of electrolyte solutions containing high con-
centrations of sodium and glucose was acceptable. Intake of signiﬁcant volumes of
ﬂuid with meals was also discouraged to minimise ECF and stoma output. The
antimotility agents loperamide (64 mg daily) and codeine phosphate (240 mg
daily) were utilised to decrease ECF output when the above measures were not
successful, as were proton pump inhibitors which helped to minimise gastric
secretions.
2.3. Intravenous nutrition
When intravenous nutrition was necessary a regimen was utilised that included
lipid and glucose calories, trace elements, amino acids and both fat- and water-
soluble vitamins. Dedicated central lines were inserted under ultrasound guid-
ance to facilitate administration of intravenous nutrition. Line handling was per-
formed only by patients or staff trained speciﬁcally in the use of central venous
catheters.
2.4. Sepsis control
Patients with clinical or laboratory indicators of sepsis were imaged by
double contrast-enhanced CT scan of the abdomen and pelvis. When intra-
abdominal or pelvic sepsis was identiﬁed, broad spectrum antibiotics were
administered and any collections were drained under ultrasound or CT imaging
guidance. When interventional radiology techniques were unsuccessful, patients
required surgical drainage with faecal stream diversion. Intravenous feeding was
discontinued in cases of line-associated sepsis and broad-spectrum antibiotics
were also administered via the central venous catheter in keeping with the
advice of our microbiology service. Feeding lines were removed in cases of
recalcitrant sepsis.
Prophylactic antibiotics were given to all patients following induction of
anaesthesia as part of the World Health Organization (WHO) checklist.
2.5. Wound care
Specialist stoma nurses managed skin andwound care with the assistance of our
tissue viability services where necessary. Large wound defects were managed with
wound manager systems. Despite recent advances in vacuum-assisted closure de-
vice technologies these devices were expressly prohibited from use in our patient
cohort.2.6. Delineating anatomy of the ﬁstulous disease
ECF anatomy was delineated utilising a combination of clinical examination and
a number of radiological investigation modalities, which included ﬁstulograms, CT
andMRI scans of the abdomen and pelvis. Multiple imagingmodalities were utilised
to visualise the gastrointestinal anatomy associated with the ﬁstulous disease, with
speciﬁc reference to additional structural abnormalities such as strictures, anasto-
motic leaks from prior anastomoses or distal obstruction.
2.7. Timing of surgery
Surgical intervention for patients with ECF that failed to close spontaneously
was performed a minimum of 6 months after their most recent laparotomy, or if the
ﬁstulous disease did not occur as a result of surgery, at least 6 months after the ECF
had arisen. This period was used to allow ﬁstula maturation, resolution of inﬂam-
mation and sepsis and return of the physiological and nutritional status of the pa-
tient, as close as possible, to their pre-morbid state. Furthermore, it has been
suggested that the abdominal environment is less “hostile” with less induration
after this time period.3
2.8. Surgical procedure to repair the ﬁstulous disease
Surgical correction mandated total adhesiolysis with en bloc resection of the
ﬁstulous disease and the associated skin. When diseased bowel was identiﬁed
during the laparotomy additional bowel resections were performed as necessary.
Elective faecal stream diversion was performed for patients with multiple co-
morbidities, those undergoing construction of more than one colonic anastomosis,
ongoing sepsis or a serum albumin level <30 g/l. Faecal stream diversion was
considered for all patients with Crohn’s disease but was not considered mandatory.
Patients with abdominal wall defects not amenable to primary closure underwent
total abdominal wall reconstruction with or without biological/prosthetic mesh.
2.9. Study end-points
The primary end point of this study was successful ECF closure. Secondary
outcome measures included: incidence of successful surgical closure; number of
surgical procedures required for successful ECF closure; incidence of spontaneous
closure; ICU requirement; organ support; time of ECF diagnosis to deﬁnitive pro-
cedure; utilisation of interventional radiological procedures; use of in hospital
intravenous nutrition; requirement for home intravenous nutrition; intravenous
nutrition complications; re-ﬁstulation; and, morbidity and mortality data.
2.10. Data analysis
Analyses were performed using a commercially available software package
(Prism 4.0: GraphPad Software, San Diego, CA). Data normality was assessed using
the De Agostino- Pearson omnibus normality test. Non-Gaussian data are presented
as median and range.
3. Results
3.1. Demographics
Forty-one patients (median age 54 years, range 16e81) with
established enterocutaneous ﬁstula(e) (ECF) were treated in our
unit over the six-year period. Demographic data are summarized in
Table 1. Seven patients (17%) developed spontaneous ﬁstulation
secondary to Crohn’s disease. The remaining thirty-four patients
(83%) developed ﬁstulae as a result of previous abdominal surgery.
The median number of ﬁstulae per patient was 1(1e3), with thirty-
Table 2
Diagrammatic illustration of outcomes of ECF patients..
n=41 
patients with ECF 
included in the analysis
n=25
eligible for surgical 
intervention
n=5 
died preoperatively 
n=19 
underwent definitive 
surgical intervention
n=6 
declined surgery and 
opted for conservative 
n=11
spontaneous fistula 
closure
n=15
complete resolution 
n=4 
recurrence
Table 3
Postoperative complication rates for n ¼ 19 patients who underwent surgical ECF
closure.
Complication Number
Minor superﬁcial wound dehiscence 5 (26%)
Bleeding abdominal wound 1 (5%)
Pneumonia 1 (5%)
Pulmonary embolus 1 (5%)
Superﬁcial fascio-cutaneous ﬂap necrosis 1 (5%)
Clostridium difﬁcile enteritis 1 (5%)
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remaining two patients had both small and large bowel ECF. Me-
dian peak ﬁstula output prior to deﬁnitive management was 2000
(425e6700) ml/day.
3.2. Preoperative management
Approximately half (19/41, 46%) of all patients were referred to
our service during the acute sepsis phase following ECF develop-
ment. Fourteen patients (34%) developed new episodes of intra-
abdominal sepsis as diagnosed by cross sectional imaging after
referral. The overwhelming majority of these episodes were suc-
cessfully treated using a combination of broad spectrum intravenous
antibiotics and interventional radiological techniques, requiring a
median of 1 (range, 0e6) percutaneous procedures per patient. One
patient required a laparotomywithdefunctioning proximal stoma to
control intra-abdominal sepsis. Nevertheless, despite these mea-
sures ﬁve patients (12%) succumbed to uncontrollable sepsis.
All patients required intravenous nutrition during the initial
evaluation and stabilization period prior to deﬁnitive treatment;
however, patients were encouraged to continue oral intake as
tolerated. High-caloriﬁc oral supplementation drinks and yoghurts
were prescribed for all patients. Median serum albumin levels at
diagnosis were 28 (range, 14e46) g/L with a median BMI of 27
(range,14e33). When the combined 24-h output of both stoma and
ECF reached the threshold of >1.5 L/day pharmacological modu-
lators of the GI tract were utilised, including: proton pump inhi-
bition e 37/41(90%); loperamide e 35/41(85%); and, opiates e 24/
41(59%). A trial of octreotide was instituted for all patients with
stoma/ﬁstulae producing >1 L/day despite these interventions;
however, this therapy failed to make a clinically signiﬁcant
decrease and was discontinued after a 72-h trial period in all cases.
Consequently, a restriction of 0.5 L/daywas instituted on oral intake
of low-sodium ﬂuids for this patient group. After oral intake and
stoma/ﬁstulae output was stabilised, 5 (12%) patients were dis-
chargedwith home intravenous nutritionwhilst awaiting deﬁnitive
surgical repair. Intravenous nutritionwas temporarily discontinued
a median of 1 (0e8) times per patient for line related sepsis, which
resulted in brain abscesses in one case that were successfully
treated following line removal and intravenous antibiotics. Recur-
rent feeding line sepsis was identiﬁed in a further three cases
requiring removal of the feeding line without additional compli-
cations. One patient developed signiﬁcant derangement of liver
function tests while receiving intravenous nutrition, which resulted
in discontinuation of this therapy.
3.3. Long-term conservative management
For eleven patients (27%) the ECF closed spontaneously with
conservative management strategies within four to six months and
not earlier. Six patients with persistent ﬁstulous disease (15%)
refused surgical intervention and remained on conservative mea-
sures and home intravenous nutrition.
3.4. Deﬁnitive surgical repair
The remaining nineteen patients (46%) were offered deﬁnitive
surgery to excise and repair the ECF (Table 2). Deﬁnitive surgical
repair was delayed for a median of 22 (range: 6e193) months after
the last laparotomy or the spontaneous occurrence of the ﬁstulous
disease. Median operative duration for deﬁnitive surgery was 285
(165e660) minutes. Three patients (7%) were defunctioned with a
stoma proximal to the site of the ﬁstula resection. Five patients
(12%) required a prosthetic mesh to facilitate abdominal wall
closurewhile the abdominal wall was reinforced by biological meshfor a further two patients (5%). One patient required a fascio-
cutaneous ﬂap to achieve wound closure. Eight patients (20%)
required admission to the intensive care unit postoperativelywith a
median stay of 14 (range: 4e22) days. All of these patients required
initial inotropic support with four (10%) requiring additional renal
replacement therapy. The median inpatient stay after surgery was
33 (2e196) days. Median serum albumin levels at discharge from
hospital were 41 (18e58) g/L with a median BMI of 22 (12e30).
3.5. Procedure related morbidity and mortality
Two patients required emergency operations in the immediate
postoperative period: debridement of a fascio-cutaneous ﬂap; and,
exploration of a bleeding abdominal wound. Eight patients (42%)
developed post-operative complications: 5 e minor superﬁcial
wound dehiscence after surgery; 1 e pneumonia; 1 e pulmonary
embolism; and, 1 e Clostridium difﬁcile enteritis (Table 3).
No operative mortality was encountered in this patient cohort.
The postoperative mortality in our series was 11% (2/19 patients):
pulmonary oedema secondary to acute left ventricular failure with
pre-existing ischaemic heart disease; and, pulmonary embolus
despite DVT prophylaxis resulting in acute respiratory distress
syndrome.
3.6. Medium-term surgical outcome measures
The median follow-up period for this patient cohort was 3.7
(1.7e6.5) years. The overall ECF closure rate in this patient cohort
was 64% (26/41). When assessing only those patients who under-
went surgical intervention, ﬁfteen patients (79%) had successful
ECF excision with complete resolution of ﬁstulous disease. Four
patients (21%) developed recurrent ﬁstulation after surgery from
the site of the surgical anastomosis during the follow-up period.
4. Discussion
This study demonstrates that a combinedmultidisciplinary team
approach results in acceptable closure rates comparable to the ones
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surgical healing rate in our cohort was 79% compared to rates of just
over 80% for the specialist units. Furthermore, the rates of morbidity
and mortality for our cohort were also comparable with those re-
ported by the national UK centres.3,18 In particular, the absence of
intra-operative mortality in our study compares very favourably
with the rates reported from specialist ECF centres (operative
mortality: 3%e3.5%).3,17,18 Nevertheless, post-operative mortality
was encountered as a result of cardio-respiratory complications,
and thus operative intervention for ECF continues to be associated
with signiﬁcant risk. In addition, this study has demonstrated once
again that uncontrollable sepsis is the most common morbidity
encountered by this patient group. This complication was respon-
sible for the death of ﬁve patients preoperatively, reﬂecting the poor
nutritional status and physiological parameters that are frequently
associated with this disease process. It is likely that preoperative
sepsis relatedmortality rates reported by regional ECF centres more
accurately reﬂect the true prevalence of this complication, as pa-
tients cannot be transferred to national centres until such time as
their physiological parameters are stabilised. Consequently, reports
from supra-regional centres are likely to underestimate the inci-
dence of sepsis related preoperative mortality in the acute phase of
ECF development. Furthermore, some authors report that post-
operative ECF-related mortality relates only to the presence of a
pre-existing comorbidity,19 which would be in keeping with the
mortality and morbidity data reported by this study.
Three quarters of patients in this study who underwent deﬁn-
itive surgery for ECF were ultimately cured of their ﬁstulous dis-
ease. Factors that might contribute to the successful operative
resolution of ECF in our patient cohort may include the now well-
established policy to delay deﬁnitive surgery where possible for
at least 6 months from the last laparotomy, or the time of sponta-
neous ﬁstulation. This permits optimisation of the patients’ nutri-
tional status, maturation of the ﬁstulous disease, in addition to
improvement of residual intra-abdominal adhesions and sepsis.
Clinical indicators of a ‘favourable abdomen’ following deferment
of surgery include prolapse of the ﬁstulous disease and resolution
of dense abdominal wall induration other than that associated with
the periﬁstulous skin.17
In addition to those patients who underwent successful surgical
repair, approximately one third of our patient cohort had sponta-
neous closure of their ﬁstulous disease and thus did not require
deﬁnitive surgical repair. While our study population was not suf-
ﬁciently large to justify analyses thatmight determine predictors for
spontaneous closure, previous studies have addressed this question.
Logistic regression analyses have demonstrated that the presence of
an intact abdominal wall and the administration of intravenous
nutrition independently predict spontaneous ECF closure.20 In
contrast, negative predictivemarkers for conservativemanagement
strategies or successful surgical intervention include: high output
ﬁstula(e), complexity of the ﬁstulous disease (multiple ﬁstulae or
the presence of an associated abscess cavity), abdominal wall de-
fects, ongoing sepsis and low preoperative albumin levels.19,20
A further noteworthy ﬁnding identiﬁed by our studywas that no
patients required intravenous nutrition after deﬁnitive surgery.
These data contrast with previous studies that report up to 10% of
patients continue to require long-term intravenous nutrition after
deﬁnitive intervention.3,6,11 Consequently, we would concur with
more recent reports that questionwhether the ability to offer home
intravenous nutrition services to a large number of patients should
be a prerequisite prior to certiﬁcation of a regional ECF unit.14
In summary, the data presented by this study conﬁrm that
themultidisciplinarymanagement of ECF patients outside a national
centre can result in acceptable surgical outcomemeasures, compared
with national standards, as discussed above. Consequently,appropriately selected ECF patients, with or without concomitant
type II intestinal failure, do not necessarily require treatment in one
of the two supra-regional nationally-designated units in the UK. This
ﬁnding has signiﬁcant implications for the improvement of service
provision capacitywithin the UKNational Health Service, in addition
to the provision of specialist treatment for the patient closer to their
home and family.5. Conclusion
This study has demonstrated that ECF patients with Type II in-
testinal failure can be successfully managed in a regional unit with
the appropriate expertise. Furthermore, surgical outcomemeasures
compare favourably with national standards. Nevertheless, these
patients often require considerable diagnostic and therapeutic in-
terventions. Therefore, appropriate management of this condition
remains critically dependant upon a dedicated multidisciplinary
team comprised of colorectal surgeons, gastroenterologists, inter-
ventional radiologists, specialist nursing staff, dieticians and
pharmacists.
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